All In Biotech

Drug Trial Radar · NCT04842877

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

141

Planned (sponsor's estimate)

Start

Jun 11, 2021

Primary completion

Dec 3, 2024

Study completion Oct 2026

Sponsor

Lead sponsor
The Lymphoma Academic Research OrganisationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Daiichi Sankyo
First posted
Apr 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, prospective, single arm, non-randomized, open-label, phase 2 clinical study to evaluate safety and efficacy of valemetostat tosylate (DS-3201b) in patients with relapsed or refractory B cell lymphoma with 6 cohorts of patients including 2 biology-driven cohorts. Up to 141 patients will be enrolled in 6 different cohorts (40 patients with aggressive B-cell lymphoma, 41 with follicular lymphoma (FL), 20 with Mantle Cell Lymphoma (MCL) and 20 with other indolent lymphomas, and 20 patients with Hodgkin lymphoma (HL)). FL patients with EZH2 mutant (gain of function mutations) will be enrolled in the cohort 2bis. At least 8 aggressive B-cell lymphoma patients with EZH2 mutant will be enrolled in the cohort 1. The primary endpoint is the overall response rate (ORR) determined by investigator assessment.

Conditions

  • Lymphoma, B-Cell

Interventions

  • Valemetostat tosylateDrug

    200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: when mature response rate data have been observed, estimated as no later than 12 months after the last patient in each cohort has received the first dose of study drug

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • A.Z. Sint Jan AV

    Bruges, Belgium

  • University Hospital Gent

    Ghent, Belgium

  • CH Tourelle Peltzer

    Verviers, Belgium

  • CHU Mont-Godinne

    Yvoir, Belgium

  • CH d'Avignon

    Avignon, France

  • CH de la Côte Basque

    Bayonne, France

  • Institut Bergonié

    Bordeaux, France

  • Institut d'Hématologie de Basse Normandie

    Caen, France

  • Ch Metropole Savoie - Site Chambery

    Chambéry, France

  • CHU d'Estaing

    Clermont-Ferrand, France

  • François Lemonnier

    Créteil, France

  • CHU de Dijon

    Dijon, France

  • Chd de Vendee

    La Roche-sur-Yon, France

  • Clinique Victor Hugo

    Le Mans, France

  • Service des Maladies du Sang - CHRU de Lille

    Lille, France

  • Institut Paoli Calmette

    Marseille, France

  • CHU de Montpellier

    Montpellier, France

  • Gh Region Mulhouse Et Sud Alsace

    Mulhouse, France

  • CHU Hôtel Dieu

    Nantes, France

  • Emmanuel Bachy

    Pierre-Bénite, France

  • CHU Pontchaillou

    Rennes, France

  • Ch de Bretagne Atlantique -

    Vannes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.